ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer®discovery technology, which enables the development of a new class of biopharmaceuticals. The Company has initially applied this technology to chemokines, a large class of pro-inflammatory and pro-migratory proteins, which can be modified using the technology, converting them into anti-inflammatory decoy proteins. The company's lead program based on this technology is PA401, a first-in-class biological that is in pre-clinical development for COPD and other lung diseases where neutrophils cause chronic lung damage.
Over 40 chemokines have been identified to date and they represent a high priority target class for a number of major pharmaceutical companies in respiratory disease, autoimmune/ inflammatory diseases (AAIDs), stem cell mobilisation, cancer and HIV. The CellJammer® discovery technology enables ProtAffin to discover and develop biopharmaceuticals with a novel mechanism of action which may avoid a number of the problems currently experienced by industry using more traditional modalities to targetchemokine activity.
Prof. Andreas Kungl, CSO of ProtAffin commented: "We are very excited by this important broad grant of patent claims protecting our CellJammer® discovery technology. We have identified a novel way to down-regulate chemokine activity by using biopharmaceuticals based on decoy chemokines which target glycans. Our lead program PA401, a decoy IL-8 protein, has already generated exciting 2efficacy data in preclinical models of COPD, showing differentiated pharmacology compared to other established anti-inflammatory therapies. Following the broad grant of claims for our unique approach to discovering biopharmaceuticals in respiratory and AAID, we look forward to discussing with interested Pharmaceutical and Biotech companies the potential to collaborate in the discovery and development of differentiated biologics which could offer specific advantages over monoclonal antibodies and small molecule therapeutics."
SOURCE ProtAffin AG
ProtAffin AG，一家生物技术公司，开发新的生物制药和肿瘤，呼吸系统疾病，炎症，今天宣布，它已被授予专利权的专利厅重点由欧洲保护其CellJammer ®发现技术，使生物制药发展的一个新类。公司已初步应用这一技术，趋化因子，一亲炎症和亲大迁徙类蛋白质，它可以修改使用的技术，转化为消炎诱饵蛋白它们。该公司的首席程序基于该技术的是PA401，先入级的生物，在临床前开发慢性阻塞性肺病和其他肺部疾病如慢性肺中性粒细胞造成损害。
趋化因子超过40个已确定的日期和它们代表的大型制药公司在呼吸系统疾病，数一高优先目标类自身免疫性/炎症性疾病（AAIDs），干细胞动员，癌症和艾滋病毒。发现的CellJammer ®技术使ProtAffin发现和开发活动的生物制药与机制的行动，一种新型可避免趋化因子的数字，目前遇到的问题，按行业使用更多的传统方式的目标。